Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio's stock surged 60% following positive Phase 2 data for Bempikibart, a potential rival to JAK inhibitors in treating alopecia areata.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Q32 Bio has announced positive 36-week topline results from Part B of the SIGNAL-AA clinical trial. The trial focused on Bempikibart for the treatment of severe alopecia areata, reporting meaningful hair regrowth and safety.
Coverage from Fierce Biotech, Yahoo Finance, and TradingView emphasizes the drug's potential to compete with JAK inhibitors. Additionally, StocksToTrade noted the company's cash-rich balance sheet and stock volatility.
Market analysts are reacting to the data, with Oppenheimer maintaining its rating and raising the price target to $40, according to GuruFocus.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drug was tested in the SIGNAL-AA trial?
The trial tested Bempikibart for the treatment of alopecia areata.
What were the results of the 36-week data?
Bempikibart achieved safety and meaningful hair regrowth in cases of severe alopecia areata.
How did the market react to the announcement?
Q32's stock jumped 60%, and Oppenheimer raised its price target for the stock to $40.
Coverage (5)
- QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet StocksToTrade · 11h ago
- QTTB: Bempikibart achieved meaningful hair regrowth and safety in severe alopecia areata at 36 weeks TradingView · 11h ago
- QTTB Maintained by Oppenheimer -- Price Target Raised to $40 GuruFocus · 11h ago
- Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Yahoo Finance · 11h ago
- Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors Fierce Biotech · 11h ago
Topics
Related trends
‘Michael’ Surpasses ‘Oppenheimer’ as Highest-Grossing Biopic With $977 Million Worldwide
The film 'Michael' has become the highest-grossing theatrical biopic of all time, earning $977 million worldwide.